Ilika’s Stereax and Goliath Units Ignite Revenue Stream in Solid‑State Battery Market

UK‑based Ilika PLC is ushering in a new revenue era for solid‑state battery technology through commercial milestones in its Stereax and Goliath programmes.

Stereax’s Move to Commercial Production

CEO Graeme Purdy frames the shift to commercial production as the company’s first genuine cash‑flow driver.

■Supplying commercial‑grade electrodes to Cirtec for the M300 medical device.

■Recognised £100,000 of revenue in the last financial year, signalling early growth.

■Anticipated royalty streams from end‑product sales within the next 12‑18 months.

Goliath Prototypes Capture New Market Segments

While the 10 Ah cells were originally built for the EV roadmap, interest from defence and e‑bike sectors is opening a diversified revenue channel.

■10 Ah prototypes shipped to OEMs and commercial customers for validation.

■Positive feedback from defence contracts and consumer e‑bike manufacturers.

■Recent fundraising proceeds earmarked to scale up production.

Financial Outlook and Strategic Implications

Ilika aims to bolster liquidity and uplift its share price by monetising both programmes.

■Projected incremental revenue of £200,000‑£300,000 over the next 12‑18 months.

■Expected royalty rates in the 5‑7 % range.

■Long‑term ambition to cement a leadership position in the solid‑state battery arena.

Gökberk Uçar: Ilika’s progress in Stereax and Goliath marks a pivotal inflection point for commercialising solid‑state batteries. The medical‑device integration and defence/e‑bike diversification will broaden the revenue base, dampen volatility, and heighten appeal for long‑term investors. From an air‑freight logistics perspective, these high‑energy‑density cells could unlock new cargo‑handling scenarios and create synergistic opportunities across the aviation supply chain.